Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
Abstract Background Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and safety of adjuvant nivolumab with other approved t...
Main Authors: | Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-020-07538-1 |
Similar Items
-
Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
by: Bruno Bregman, et al.
Published: (2020-09-01) -
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
by: Ravi Potluri, et al.
Published: (2019-07-01) -
308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma
by: Dirk Schadendorf, et al.
Published: (2020-11-01) -
Multimodal therapy with surgery and adjuvant nivolumab for late-onset multiple liver metastases of choroidal malignant melanoma: a case report
by: Ryuta Muraki, et al.
Published: (2020-07-01) -
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
by: Jin CH, et al.
Published: (2016-03-01)